Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eurofins Scientific SEERFSF -0.96%77 3-Year EPS without NRI Growth Rate is 5.40% as of Jun. 2026, which is 78% below its 10-year median of 24.50. GuruFocus rates ERFSF with a GF Score™ of 77/100 and a GF Value™ of $75.69 (Fairly Valued). The stock has 6 warning signs investors should review. Among 157 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 57.32% on this metric.
During the past 12 months, Eurofins Scientific SE's average EPS without NRI Growth Rate was 12.30% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 5.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -1.80% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 14.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Eurofins Scientific SE was 341.40% per year. The lowest was -11.20% per year. And the median was 24.50% per year.
Eurofins Scientific SE (OTCPK:ERFSF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Eurofins Scientific SE 3-Year EPS without NRI Growth Rate Related Terms
ERFSF vs TMO, DHR, IDXX: 3-Year EPS without NRI Growth Rate Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE 3-Year EPS without NRI Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's 3-Year EPS without NRI Growth Rate falls into.
Eurofins Scientific SE 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 5.40% mean?
Eurofins Scientific SE (ERFSF) has a 3-Year EPS without NRI Growth Rate of 5.40% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Eurofins Scientific SE and its competitors. This is 78% below median its historical median of 24.50. According to the industry distribution chart, Eurofins Scientific SE ranks #90 out of 157 companies in the Medical Diagnostics & Research industry, placing it in the top 57.3%.
Is Eurofins Scientific SE's 3-Year EPS without NRI Growth Rate too high?
Eurofins Scientific SE's current 3-Year EPS without NRI Growth Rate of 5.40% is 78% below median its 10-year median of 24.50. The Medical Diagnostics & Research industry median 3-Year EPS without NRI Growth Rate is 10.80. Eurofins Scientific SE's value of 5.40% is 50% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #90 out of 157 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Eurofins Scientific SE has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's 3-Year EPS without NRI Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #90 out of 157 companies for 3-Year EPS without NRI Growth Rate. This places Eurofins Scientific SE in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 10.80. Eurofins Scientific SE's value of 5.40% is 50% below this benchmark. While the company's 10-year median is 24.50 vs. the industry median of 10.80, Eurofins Scientific SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EPS without NRI Growth Rate among Medical Diagnostics & Research companies is 10.80, based on 157 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current 3-Year EPS without NRI Growth Rate of 5.40% is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EPS without NRI Growth Rate is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current 3-Year EPS without NRI Growth Rate is 5.40%, which is 78% below median its own 10-year median of 24.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Fairly Valued. The stock's GF Value™ is $75.69, compared to a current price of $81.69 — trading 7.9% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 5.40%, which is 78% below median its 10-year median of 24.50 and 50% below the Medical Diagnostics & Research industry median of 10.80. Eurofins Scientific SE's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current 3-Year EPS without NRI Growth Rate is 5.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $81.69 is trading 7.9% above its estimated GF Value™ of $75.69.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for ERFSF:
3-Year EPS without NRI Growth Rate: 5.40% (78% below median its 10-year median of 24.50)
GF Value™: $75.69 vs. price of $81.69 (7.9% above fair value)
Industry Position: 50% below the Medical Diagnostics & Research median (#90 of 157)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
77GF Score
Get the complete analysis for ERFSF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
